ClearColi BL21(DE3)-based expression of Zika virus antigens illustrates a rapid method of antibody production against emerging pathogens
Abstract
No abstract availableKeywords
Funding Information
- ZIKAVAX (151567A10-ZIKAVax)
- ZIKAlliance project (735548)
This publication has 15 references indexed in Scilit:
- The South Pacific epidemic strain of Zika virus replicates efficiently in human epithelial A549 cells leading to IFN-β production and apoptosis inductionVirology, 2016
- Recombinant human HSP60 produced in ClearColi™ BL21(DE3) does not activate the NFκB pathwayCytokine, 2015
- Protein recovery from inclusion bodies of Escherichia coli using mild solubilization processMicrobial Cell Factories, 2015
- Comprehensive mapping of a novel NS1 epitope conserved in flaviviruses within the Japanese encephalitis virus serocomplexVirus Research, 2014
- Flavivirus NS1 Structures Reveal Surfaces for Associations with Membranes and the Immune SystemScience, 2014
- Animal models of sepsisVirulence, 2013
- Antibodies against West Nile Virus Nonstructural Protein NS1 Prevent Lethal Infection through Fc γ Receptor-Dependent and -Independent MechanismsJournal of Virology, 2006
- Combination of Dsb coexpression and an addition of sorbitol markedly enhanced soluble expression of single‐chain Fv in Escherichia coliBiotechnology and Bioengineering, 2005
- A Functional Epitope Determinant on Domain III of the Japanese Encephalitis Virus Envelope Protein Interacted with Neutralizing-Antibody Combining SitesJournal of Virology, 2003
- The antigenic structure of dengue type 1 virus envelope and NS1 proteins expressed in Escherichia coliJournal of General Virology, 1990